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Access to many controlled medicines is inadequate in a number of European 
countries. This produces deficits in the treatment of moderate to severe pain as well 
as in opioid agonist therapy. To elaborate the reasons offor this inadequacy, the work 
plan of the Access to Opioid Medication in Europe (ATOME) project included two six-
country workshops . These workshops includedto conduct a national situational 
analysis, and to elaborate tailor-made recommendations for improvement and drafts 
of action plans for their implementation. In total, Eighty-four84 representatives of the 
national Ministries of Health, national controlled substances authorities, experts 
representing regulatory and law enforcement authorities,  and leading healthcare 
professionals, and patient representatives from thirteen European countries 
participated in eitherone of the workshops. The delegates utilized break-out sessions 
to identify key Common challenges that could be identified during the ATOME 
workshops were a number ofto opioid accessibility in their country ion the 
domainlevel of knowledge and educational, regulation and ory, legislationna, as well 
as public awarenessl and training barriers that limit opioid prescription. In addition 
short validity and bureaucratic practices resulting in an overregulation impeding 
availablity of some essential medicines. In relation to opioid agonist therapy, 
stigmatization and criminalisation of people who use drugs remained the major 
impediment to increasing programme coverage. The challenges identified 
duringoutcomes of the workshops were the basis for furtherused to inform 
subsequent dissemination and implementation activities in the ATOME project, and 
in some countries already theserved as a stepping stone for the first changes in 













Identification of challenges to the availability and accessibility of 
opioids in twelve European countries: conclusions from two 
ATOME six-country workshops 
Background 
With the exception of some Western industrialized countries, access to many 
controlled medicines is inadequate around the world [1,2]. The World Health 
Organization (WHO) estimates that approximately five billion people live in countries 
with low or no access to controlled medicines [3] and insufficient access to treatment 
for moderate to severe pain is reported in more than 150 countries. In 12 countries of 
the European Union (EU), opioid analgesic consumption is described as ´low to very 
low´ [4]. 
In addition to pain management, opioids are also needed for in the treatment of 
opioid dependence, mainly substitution programmes like thefor opioid agonist 
therapy (OAT) for drug users. Access to OAT in the EU varies dramatically. In some 
Central and Eastern European countries, less than 10% of people who would benefit 
from opioid agonist therapy are reached. Where harm reduction programmes exist, 
access is impeded by lengthy waiting lists, strict admission criteria, and lack of 
evidence-based standards for provision and quality of care; those at the greatest risk 
of exclusion are women, young people and migrants [5]. 
The European Commission’s 7th Framework programme funded the Access to 
Opioid Medication in Europe (ATOME) project (2009-2014, www.atome-project.eu). 
Its objective wais to improve access to opioids in 12 European countries (Figure 1) 
where there has been statistical evidence of low per capita morphine consumption at 
the time of the project submission (09.2009): Bulgaria, Cyprus, Estonia, Greece, 
Hungary, Latvia, Lithuania, Poland, Slovakia, Slovenia, Serbia and Turkey. 
The work plan of the ATOME project (Figure 1) included two international six country-
workshops as the foundation of subsequent activities directed at improving national 
policies related to opioid access. This article aims to describe the main challenges to 
opioid availability and accessibility identified during these two workshops and the 
recommendations for improving access to opioids that were made by the participants 
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As a part of this project two international six country-workshops were organised 
Country teams had been composed at the outset of the work programme to ensure 
country-specific relevance and applicability of the project activities; the teams 
included representatives of the national Ministries of Health; national controlled 
substances authorities; experts representing regulatory and law enforcement 
authorities; leading healthcare professionals; and patient representatives. The six-
country workshops were held in Bucharest, Romania in September and November 
2011, with the purpose to 1) assist expert delegations to undertake national 
situational analyses, 2) disseminate tailor-made recommendations to their national 
governments for improving the accessibility, availability and affordability of controlled 
medicines and 3) plan how to implement these improvements. with the aim to 
undertake national situational analysis, make tailor-made recommendations for 
improvement and develop action plans to implement these recommendations. This 
article aims to describe the main challenges to opioid availability and accessibility 
that were identified during these two workshops and the recommendations for 
improving access to opioids that were made by the participants of the workshops.  
 
Methods 
Two six country-workshops were organized in Bucharest, Romania in September and 
November 2011, with the purpose to: 
(1) assist expert delegations to undertake national situational analyses  
(2) disseminate tailor-made recommendations to their national governments for 
improving the accessibility, availability and affordability of controlled medicines 
(3) plan how to implement these improvements.  
Additionally, awareness about tools and resources was intended to be raised.  
The guiding principle of each workshop was tThe principle of balance in national 
opioid policy, i.e. the obligation ofn each government to ensure availability and 
accessibility of opioids while preventing abuse and diversion was the guiding 
principle in both workshops. The workshops were designed as two-and-a-half day 
events with a combination of lectures from international experts (total duration: 5,5h) 
and discussion groups where theto analyze the national situation was analyzed 
regarding access to opioids, identify identify potential problems, and decide on 
furtheraction steps to improve the situation (total duration: 8h) were prepared. 
Representatives from the ATOME consortium and the workshop faculty assisted the 
group work as facilitators. The country teams presented the outcomes of their group 
work in plenary, followed by a discussion and feedback from the other delegations 
(total duration: 3,5 hours). Tools such as the WHO checklist for national situation 
analysis [7]; a case example of a patient in order to discuss the national situation in a 
problem-based manner; and a strategic action planning worksheet were used in the 
discussion groups in order to guide the process of tailoring country-specific solutions. 
Material relevant to the accessibility and availability of opioids, such as scientific 
articles or position papers, was provided to participants prior to the workshop. The 
country teams presented the outcomes of their group work in plenary. Tools such as 
the WHO checklist for national situation analysis [8]; a case example of a patient in 
order to discuss the national situation in a problem-based manner; and a strategic 
action planning worksheet were used in the discussion groups in order to guide the 
process of tailoring country-specific solutions. The results of this article have 
beenwere condensed from the country teamsteam’steams’ presentations, action 
plans and minutes from the group work sessions. The workshops wereas evaluated 




In total, 39 representatives from Bulgaria, Cyprus, Greece, Turkey, Serbia and 
Slovenia attended the first workshop, and 45 peopledelegates from Estonia, 
Hungary, Latvia, Lithuania, Poland and Slovakia attended the second one. Ukraine 
(which was not oneamong of the target countries) sent observers to the second 
workshop. Participants forming the country teams were representatives from the 
national Ministries of Health, national controlled substances authorities, experts 
representing regulatory and law enforcement authorities; and leading healthcare 
professionals.  
The national delegations utilized break-out sessions to analyse country-specific key 
challenges to opioid accessibility and to elaborate strategic action plans for 
improvement, which were subsequently presented and discussed in plenary. 
  
IdentifiedKey challenges 
Lack of education, excessive regulations relating to the prescribing of opioids, 
“opiophobia” – fear from opioids and lack of reimbursement were  
The most frequently identified as challenges to concerning access to opioids by 50-
75% of the country teams , see (Table 1). during the ATOME workshops are:  
 
Table 1 shows the most frequently identified challenges and recommendations for 
improvement made The most frequently  
lack of education (identified by 9 country teams); excessive regulations relating to the 
prescribing of opioids (identified by 8 country teams); “opiophobia” (identified by 7 
country teams); lack of reimbursement (identified by 6 country teams); lack of 
knowledge about opioids amongst patients, their family and society; lack of 
recognition of pain management; limitations to the formulary availability of opioids; 
excessive regulations relating to storage and dispensing of opioids; lack of opioid 
legislation/inappropriate legislation; and treatment of pain in non-cancer patients 
(identified by 5 country teams). All challenges that were highlightediIidentified 
challenges during the workshops are presented below and in Ttable 1, followinged by 
recommendations for improvement made by the participants.  on how to deal with 
these challenges. TThe names of the countries mentioned in the following 
paragraphs can be seen as exemplary; because the the suggestions may relatehave 
been given by one or more countries during the workshops but can it can be 
assumed to be applicable to many other countries as well. 
 
Lack of education and training on opioid medicines and their use: 
Lack of education and Iinadequate and inconsistent training of physicians in pain 
management results in a lack of knowledge regarding the correct dosage of opioids. 
Where education initiatives exist, they are usually subsumed within the training of 
other medical specialties and are often only of a few hours duration. In consequence 
many general practitioners lack expertise in prescribing opioids and usually refer this 
responsibility to oncologists. This may hamper acess to opioid medicines for patients.  
To overcome the challenge regarding the lack of opioid education and training 
initiatives for healthcare professionals, delegates from Cyprus suggested an 
obligatory examination for that aall doctors should be required by the Head of 
Pharmaceutical Services/Medical Council to pass an examination regardinglating to 
opioid prescribing. For Estonia and Hungary it was recommended by participants 
from the countries to improve opportunities for Continuing Medical Education in the 
area of pain management, whilst Hungarian delegates recommended that physicians 
should also be taught practical skills in how to apply the pharmacotherapy of pain. In 
Serbia there is a need for education/training sessions and opioid workshops amongst 
regulatory authorities that stress access to pain relief as a ´human right’. Workshop 
participants from Slovenia recommended developing a network to educate, train and 
support all members of the multidisciplinary team in prescribing.  
Lack of knowledge about opioids amongst patients, their family and society  
There is aA lack of public awareness about opioids was explicitly mentioned by 
seven country teams. This involves fears and beliefs amongst patients and their 
families, as well as and the general public. In addition attitudes and beliefs amongst 
the public in relation to opioids involve much misinformation and misunderstanding in 
the general public. Many medical professionals are afraid of prescribing opioids. This 
was explicitly mentioned by seven country teams. Societal misconceptions about 
opioids lead to negative side-effects such as the perception that suffering is normal, 
heroic or necessary. Negative stereotypes about opioids ( e.g. labelling opioid 
medicines as “narcotic drug” or “poison”) and fears about tolerance amongst patients 
and their families reinfoce this problem.In some countries, e.g. Lithuania, there was a 
perception that national policy discourse or the societal rhetoric around opioids even 
increases reluctance among general practitioners to provide pain management. 
 
Lack of recognition of pain management  
Five country teams reported that chronic pain is often neither recognised nor 
acknowledged by healthcare professionals and a sceptical attitude towards pain 
treatment is reported among many physicians. Specialists of other disciplines other 
than oncology do not always recognise the need for pain management. In some 
countries, e.g. Lithuania, there was a perception that national policy discourse or the 
societal rhetoric around opioids even increases reluctance among general 
practitioners to provide pain management. 
 
Treatment of pain in non-cancer patients  
Five countries reported that pain management for non-cancer patients is poorly 
organised. In some countries opioids are usually limited for use in terminal cancer. 
Access to palliative care for non-cancer patients is a challenge in many countries; for 
example it was reported from Latvia that opioids are not reimbursed for patients with 
non-oncological diseases except for patients suffering from HIV/AIDS. 
 
Lack of reimbursement (particularly for non-cancer patients) 
The costs of opioids, described as very high in many countries, are not always 
covered by government fundingappropriate statutory funding schemes. This was 
described as a challenge by six country teams. Particularly for people suffering from 
acute or chronic conditions due to non-oncological diseases this is a problem since 
chronic non-cancer pain in some places is not recognised as a medical condition, 
which makes reimbursement impossible. For people with low or no income, this may 
mean that they will not have access to the medicines they need. 
 
Limitations to the available range of opioids 
Lack of choice of opioids such as injectable morphine, slow-release oral morphine, 
buprenorphine and methadone was highlited as one of the challenges in 5 countries. 
As an example, in Slovenia not all medicines from the WHO essential medicines list 
were available. Even though a proposal for a new list had been drafted at the time of 
the workshop, there was concern that it will not be adhered to by the pharmaceutical 
industry. 
 
Pharmaceutical company reluctance to manufacture opioids 
In some smaller countries pharmaceutical companies have little interest in procuring 
opioids as there is only a rather small market where cost of procurement  and 
projected incomes are disproportional.This challenge was reported by three country 
teams. 
 
Excessive regulations relating to the prescribing of opioids 
Physicians often are reluctant to prescribe opioids due to excessive bureaucracy, as 
described highlighted by eight country teams. Barriers such as special prescription 
forms that need to be stored with special security measures, restrictions regarding 
the authorisation to prescribe (e.g. only designated medical specialties), excessive 
reporting requirements of opioid prescriptions, and complicated administrative 
requirements for filling out the prescriptions may result in a reluctance to prescribe 
opioids for patients in medical need. Other reported challenges to the availability of 
opioid medicines are a limited prescription validity in combination with restrictions 
regarding the maximum amount of opioids to be prescribed. In addition it was 
reported that fear of prosecution if the patient should die deters physicians from 
prescribing opioids. This may as well result in a lack of experience in prescribing 
amongst family practitioners. Excessive regulation may also affect provision of 
opioids in home care settings. 
 
Excessive regulations relating to storage and dispensing of opioids 
Five country teams reported that not all pharmacies are allowed to store opioids and 
that special storage conditions are required. Extensive bureaucracy relating to the 
dispensing of opioid medicines often results in a delay in the commencement of 
treatment with these medicines. Fear of prosecution may also deter medical 
practitioners from prescribing or dispensing opioids, such as in Greece, where 
prosecution of pharmacists for minor opioid offences is common so many 
pharmacies refuse to dispense morphine. 
 
Lack of opioid legislation/inappropriate legislation 
A lack of legislation related to the use of opioids, the lack of education that would be 
necessary to work with opioids and an outdated opioid terminology impede an 
adequate supply. Complicated legislation structures such as the involvement of three 
separate Ministries make changes in the opioid legislation extremely difficult. This 
challenge was reported by five country teams.  
 
Focus on suppression rather than availability of opioids 
Government agencies and committees tend to focus more on prevention of diversion 
and misuse rather than medical availability of opioids. National governments have 
little recognition that opioids are necessary for pain relief or that it is their obligation to 
ensure adequate availability of opioid medicines. This was reported by three country 
teams. 
 
Other challenges to the availability and accessibility of opioids identified at the 
workshops 
Other challenges identified during the workshops were difficulties in accessing 
opioids out-of-hours - particularly in rural areas because not all pharmacies stock 
opioids; an unequal geographical distribution of pain services due to financial 
reasons and a lack of trained specialists; or that patients not registered with a 
general practitioner or not admitted to hospital may not be able to get access to 
opioids. 
National approaches to solution 
To approach thedevelop national action plans the country teams completed so called 
strategic planning worksheets in group work (see Table 2).  
Table 2 Strategy planning worksheet – example education 
What? A. State the problem Education 
Why? B. State the underlying 
reason(s) for the problem 
No standard training in opioid 
analgesia in the basic 
curriculum in physicians and 
other health care professionals 
No comprehensive continuing 
education and training of 
executives involved with the 
subject 
What? 
C. State the objective(s) that 
would address the problem. 
Which objectives are top 
priorities 
Inclusion of PC and opioid 
management in the basic 
training of physicians and 
paramedics 
To overcome opiophobia 
How? 
D.What action steps are 
needed to achieve the 
objective? 
Target population of education : 
Physicians, Nurses, Social 
workers, Pharmacists, Patients 
and Families, Public 
Who? 
E. List those who have the 
authority and/or responsibility to 
take the necessary action. 
Ministry of Education 
Ministry of Health 
Ministry of Justice 
When? F. Timeline for completion of 
action steps 
September 2011-October 2012 
How Much? 
G. What technical and financial 
assistance will be needed to 
achieve each objective 
1. Ministry of Health 





Process observation made during both events by representatives of the ATOME 
consortium confirmed the particular benefit of the workshop method. The six-country 
workshops had brought together stakeholders from different areas who usually would 
not have the opportunity to exchange and share their perspectives. This also resulted 
in concrete positive effects such as in one country clarification of misunderstandings 
about the legal restrictions and unawareness of regulatory leeway regarding 
methadone prescription for pain treatment (Cyprus). 
 
Workshop evaluation 
44%FourtyfourForty-four percent (n=37) of the 84 A total of 37 participants completed 
both pre- and post-workshop questionnairesparticipants completed both pre- and 
post-workshop questionnaires, see Table 32. : 35 ThirtyfiveThirty-five of the 37 
respondents (95%) reported that their knowledge about accessibility of controlled 
medicines ‘had been enhanced’ by attending the workshop;, and 21 (57%) reported 
that their attitudes in relation to the accessibility of controlled medicines ‘had been 
changed’ by attending the workshop. 
Respondents made suggestions iIn the questionnaire, suggestions were made to 
improve the situation; countries mentioned here can be seen as exemplary; the 
suggestions are likely to relate to other countries as well. Raising public awareness 
about the beneficial effects of opioids to reduce the fear of prescribing opioids 
medicines was suggested by several teams. Concrete measures were proposed, 
such as the initiation of social campaigns counteractionto counteract myths and 
stereotypes about opioids ( Poland, Serbia, Slovakia and Turkey), or raising pressure 
from professional organisations, trade unions, patient organisations and professional 
bodies to influence political will and ensure adequate reimbursement of opioids 
(Hungary). 
 
The acknowledgement of chronic pain as a clinical problem was deemed of 
paramount importance (highlighted by a delegate from Bulgaria), and the 
development of policy guidelines in pain management in collaboration with the 
Ministry of Health to overcome barriers relatingrelated to excessive regulations was 
proposed by a representative from Cyprus. 
In the questionnaire, suggestions were made to improve the situation. Raising public 
awareness about the beneficial effects of opioids to In the questionnaire section for 
possible improvements several recommendations have been made by the country 
teams. In relation to reduce the fear of prescribing opioids was suggested by the 
Estonian team, Estonian team members.  recommended that public awareness about 
the beneficial effects of opioids should be raised on a regular basis in order to 
change attitudes. Poland, Serbia, Slovakia and Turkey suggested the initiation of that 
social campaigns counteracting myths and stereotypes about opioids should be 
initiated. Participants from Hungary recommended raising pressure from professional 
organisations, trade unions, patient organisations and professional bodies to 
influence political will and ensure adequate reimbursement of opioids.  
 
To address the challenges associated with the lack of reimbursement for opioids, 
participants from Hungary recommended that the only way that opioids can be 
adequately reimbursed is through pressure from professional organisations, trade 
unions, patient organisations and professional bodies in order to influence political 
will. Bulgaria highlighted the need to acknowledge chronic pain as a clinical problem. 
Participants from Cyprus suggested the development of policy guidelines in pain 
management in collaboration with the Ministry of Health to overcome barriers relating 
to  
 To ease the challenges from excessive regulations.  related to storage and 
dispensing of opioids, Cyprus suggested that challenges to a lack of opioid legislation 
or inappropriate legislation could be overcome by developing policy guidelines in pain 
management in collaboration with the Ministry of Health.  
 
Discussion  
The results of the workshops demonstrate underline that lack of access to opioids is 
a  multifactorial fieldin nature. Barriers exist on numerous levels which are interlocked 
and partially reinforced by each other. A strength of these workshops was therefore 
thatFor this reason, stakeholders representing as many relevant fields as possible in 
relation to access to opioids were addressed by this workshop. 
Common challenges identified during the ATOME workshops were a number of 
educational, regulatory, legislational and training barriers that limit the ability of both 
physicians and nurses to prescribe the necessary doses of opioids to patients. A 
number of publications have been produced by the European Association for 
Palliative Care (EAPC)[9,10] to overcome these challenges.  These findings are in 
line with the main barriers to opioid accessibility reported in previous publications by 
leading researchers in the field [ 11, 12, 13, 14]. 
Other fFrequently reported challenges were related to short validity of prescriptions 
and excessive bureaucratic practices when prescribing. Similar results have been 
identified in the legislation analysis by Utrecht University during the ATOME project 
as well as in the individual country reports. The issue of overregulation of opioids was 
also reviewed by Cherny, et al., [15,16,17] who reported on some elements of the 
legal and regulatory barriers to opioid availability and accessibility throughout Europe 
and the world. Unduly restrictive legislation that limits the distribution, prescription, 
dispensation, and use of opioids has been described by Joranson and Ryan [18] and 
Human Rights Watch [19]. These authors agree that in most cases the problem is it 
is not the lack of availability of opioids in the country, but rather the combination of 
many bureaucratic and legislative regulations that impede opioid prescription and 
dispensing. Many medical professionals, especially particularly family doctors, 
appear to be afraid of prescribing opioid medications, often related to these 
regulatory barriers [20]. Lynch, et al., [21] reported complicated procedures relating 
to the prescription of opioids in the countries of Central and Eastern Europe and 
Commonwealth of Independent States, where it was very difficult to obtain a license 
to prescribe opioids. 
Limited knowledge about opioid analgesics was reported in a number of countries in 
Western Europe [22], where lack of professional knowledge about the prescription of 
strong opioids may result in reluctance on the part of physicians to prescribe them. 
The relevance of such challenges to a plethora of diverse socio-cultural, economic, 
educational and health policy settings should be fully and adequately considered. 
Next to establishing national, regional, or local under- and postgraduate education 
opportunities for healthcare professionals, the availability of guidance 
papersguidelines or other guidance can be a possiblefeasible way to address 
unawareness and misinformation, such as the evidence-based guidelines by the 
European Association for Palliative Care (EAPC) on the use of opioid analgesics for 
the treatment of cancer pain [(23ref.]).  
In relation to opioid agonist therapy, stigmatization and criminalization of people who 
use drugs remain the major impediment to increasing programme coverage, 
particularly in prison settings. This manifests a lack of interest among policy makers 
to invest in evidence-based harm reduction approaches, despite the proven 
effectiveness of these programmes in preventing HIV transmission. Fear of arrest 
and police harassment among drug users may deter many from accessing these 
services [5]. 
The aims of the workshops to assist the country teams to analyse their national 
situational, disseminate country-specific national action plans and raise the 
awareness about tools and resources have been realized. The challenges reported in 
the workshops have been analyzed and have been considered in subsequent steps 
of the programme such as the national follow-up conferences. Participants' feedback 
included some criticism on the schedule (too full); or that a longer meeting time or 
repeated events over a period of time might have provided better outcomes. 
However, nearly all participants reported that their expectations for the workshop had 
been met.  
Limitations 
There are a number of limitations associated with this paper. First of all, Tthe 
selection of experts and participants attending the workshops was a potential source 
of bias as . As their views may not represent the situation in were subjective and 
isolated, they cannot be presumed to be completely representative of the countries 
concerned. However, the participants (ATOME country team members) were 
carefully selected to ensure that as many relevant fields as possible in relation to 
access to opioids were represented. This is crucial as  Iimproving access to opioids 
requires a multilevel approach since it is the outcome of a complex interaction of 
national legislation, policies and regulations, education, economy/finance, healthcare 
practice, attitudes, and social norms. In addition, close collaboration with the country 
teams during all phases of the ATOME project, including thisthe workshops, ensured 
ownership of the proposed strategies which is an important prerequisite for 
successful implementation. Therefore, stakeholders representing as many relevant 
fields as possible in relation to access to opioids were invited to these workshops. 
The setting was prepared to ensure that the situational analysis, the identification of 
problems, and proposal of solutions were developed by the national stakeholders 
themselves. 
In aAddition, there may also haveThere may have been some unintended negative 
effects during the workshops – for example the fact that data challenges provided 
reported by participants or country teams could potentially have been inflated 
suppressed by competitive tendencies between neighbouring countries. However, 
the invitation of six different countries to each workshop was also believed to 
facilitate exchange, reduce stigma, and enhance the creative development of 
solutions by learning from models in other countries, since many countries do 
encounter similar problems.  
Importantly, the challenges identified during each workshop only reflect what was 
explicitly discussed; this does not necessarily mean that the respective issues do not 
also apply to other countries– the barriers identified are not exclusive to the countries 
that reported them. 
Similar wWorkshops with similar setup have been used to compare the development 
of health care policy across both countries and regions and have come to similar 
results; most notably, those undertaken by the Open Society Foundations 
International Palliative Care Initiative and regional or national palliative care 
associations such as the African Palliative Care Association (APCA) [24,25,26] and 
the International Association for Hospice & Palliative Care (IAHPC) [27]. The 
international comparison of barriers as well as the possibility of establishing new 
contacts in a similar field of expertise seems to be a fruitful way of resolving 
widespread difficulties. 
Importantly, the challenges identified during each workshop only reflect what was 
explicitly discussed; this does not necessarily mean that the respective issues do not 
also apply to other countries– the barriers identified are not exclusive to the countries 
that reported them. 
 
Conclusion 
The participants of the country teams made use of the two six-country workshops to 
identify key challenges to access to opioids in their country and to elaborate tailor-
made strategic action plans for improvement. Findings from the country workshops 
reported here were triangulated with outcomes from related activities in the ATOME 
project, most importantly the recommendations resulting from the in-depth analysis of 
legislation [30]. The results of these workshops therefore delivered an important 
contribution to a comprehensive analysis and informed the subsequent work of the 
country teams during a series of national follow-up conferences, as well as the 
development of tailor-made recommendations and solutions for each of the twelve 
participating countries [29]. These recommendations could serve as guidance for 
other countries in the world as well.  
The WHO resolution on strengthening Palliative care, which has been adopted at the 
World Health Assembly in May 2014 in Geneva [28] gives hope that a global 
improvement of pain treatment gets to the focus of politicians and health care 
decision makers. As to the furtherThe action steps resulting from the identified 
challenges the ATOME programme developedwith tailor-made solutions for each of 
the twelve particitpatingparticipating countries that could accountcould set an 
example for other countries in the world as well that want to improve access to 
controlled medicines following the WHO resolution [29]. 
Many The challenges to access to opioids were identified during the workshops. 
These challenges, as well as key topics from the national action plans developed in 
the two workshops were used to inform the work of the country teams during a series 
of national follow-up conferences. Importantly, legislation and regulations concerning 
the use of controlled medicines have been analysed in depth by Utrecht University as 
part of the ATOME project [30]. Findings from the country workshops reported here, 
the results of the legislation review and the results of the national follow-up 
conferences have been used for triangulation. Finally, a report on the findings in each 
participating country has been compiled and will be presented to the national health 
ministries.  
The WHO resolution on strengthening Palliative care, which has been adopted at the 
World Health Assembly in May 2014 in Geneva [31] gives hope that a global 
improvement of pain treatment gets to the focus of politicians and health care 
decision makers. As to the further steps resulting from the identified challenges the 
ATOME programme developed tailor-made solutions for each of the twelve 
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Table 1: challenges concerning access to opioids identified by the country teams 
Identified challenge No. of country 
teams 
Recommendations elaborated among the 
country teams 
lLack of education: 
Inandequate training of physicians in 
pain management. Many general 
practitioners therefore refer the 
prescription of opioids to oncologists 
resulting in underprescription. 
9 
Implement opioid prescribing examination, 
improve education in the field of pain 
management, educate regulatory authorities 
to underline that access to pain relief is a 
human right, and develop a network to 








                                                                                                                                                                                              
lLack of knowledge about opioids 
amongst patients, their family and 
society: 
Fears and beliefs as well as mis-
information and misunderstanding. 
Perception that suffering is normal, 
necessary or heroic. Negative 
stereotypes about opioids (“drugs”) 
reinforce the fear of patients and 
physicians. 
7 raise public awareness about the beneficial effects of opioids 
lLack of recognition of pain 
management: 
Chronic pain and other non-
oncological diagnoses are often not 
being recognised by healthcare 
professionals. 
5 
develop policy guidelines in pain 
management in collaboration with the 
respective ministry, recognise/acknowledge 
chronic pain and pain of non-cancer as a 
clinical problem (with an ICD code if possible) 
Lack of reimbursement: 
Due to high costs opioids are not 
being reimbursed for acute or 
chronic conditions. The lack of 
recoginition of chronic non-cancer 
pain as a medical condition makes 
reimbursement impossible. 
6 
achieve adequat reimbursed through 
pressure from professional organisations, 
trade unions, patient organisations and 
professional bodies in order to influence 
political will 
Limitations to the avialable range 
of opioids: 
Lack of choice of opioids such as 
injectable morphine, slow-release 
oral morphine, buprenorphine and 
methadone. 
5 
bring the revised WHO list of essential 
medicines to the adherence of government 
representatives and the pharmaceutical 
industry 
Pharmaceutical company 
reluctance to manufacture 
opioids: 
Some pharmaceutical companies 
have little interest in procuring 
opioids as there is only a small 
market where cost of procurement 
and projected incomes are 
disproportional. 
3 
establish a reliable supply of slow-release 
oral morphine (if needed via import) and 
improve access to immediate-release opioids 
                                                                                                                                                                                              
Excessive regulations relating to 
the prescribing of opioids: 
Special prescription forms that need 
to be stored with special security 
measures, restrictions regarding the 
authorisation to prescribe, excessive 
reporting requirements of opioid 
prescriptions, complicated 
administrative requirements for filling 
out the prescriptions and limited 
prescription. 
8 
e-prescription forms should be introduced to 
enable every physician to prescribe opioids 
without having to complete a special 
prescription form 
Excessive regulations relating to 
storage and dispensing of 
opioids: 
Not all pharmacies are allowed to 
store opioids and special storage 
conditions are required. 
5 
special licensing for dispensing opioids 
should be abolished, and all pharmacies 
should be legally obliged to dispense them 
Lack of opioid legislation/ 
inappropriate legislation: 
Lack of legislation and outdated 
terminology impede an adequate 
supply. 
5 revise legislation with the aim of addressing fears and myths relating to the use of opioids 
Focus on suppression rather than 
availability of opioids: 
Government agencies tend to focus 
more on prevention of diversion and 
misuse rather than medical 
availability of opioids and have little 
recognition that opioids are 
necessary for pain relief. 
3 
education/training sessions and opioid 
workshops amongst regulatory authorities 
that stress access to pain relief as a ´human 
right’ 
Other challenges identified: 
Difficulties in accessing opioids out-
of-hours (rural areas) and a lack of 
trained specialists. 
1 all pharmacies should be permitted to stock opioids 
 
 
Table 3: Extract of results from the post-workshop questionnaire 
1. What was the most valuable aspect of the workshop? 
 Opportunity to collaborate with the government on a project 
 Exchanging information with other countries 
 Meeting people working in the same field in other countries 
 Experience of other countries and recommendations 
 I was able to convince my country team and raise awareness especially in the Ministry of Health 
                                                                                                                                                                                              
 Country action plans gave a good overview of the problematic situation 
2. What was the least valuable aspect of the workshop? 
 Too hard working the whole day requiring full concentration 
 Too crowded schedule was so exhausting – one more day would be needed to improve the 
quality of work 
 Too much time is spent on the action plan 
3. Please write down any additional comments or suggestions 
 It would be useful to know the opinions of authorities for restrictions if these are not due to 
financial problems 
 Everything was well organized; maybe more teaching, films, case examples can be included in 
the programme 
 Good balance of theory and information and practical work 
 ‘Report of status of…’ should be prepared before the workshop 
 
